← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #376 OF 1,000 MOST-CITED

Testing Each Component for Conformity with Specs

FDA cited this observation 52 times across 51 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs52
BY FISCAL YEAR
FY20264
FY202510
FY20248
FY20233
FY20225
FY20202
FY201911
FY20188
FY20171

How FDA worded it — real examples

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

Eosera, Inc. · Fort Worth, Texas · Drugs · 2026-03-20

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

Smith & Nephew Wound Management · Fort Worth, Texas · Drugs · 2026-02-26

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

Acme Generics Private Limited · Solan · Drugs · 2026-02-20

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

EO Products, LLC · San Rafael, California · Drugs · 2025-10-23

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

HTO Nevada Inc. dba Kirkman · Lake Oswego, Oregon · Drugs · 2025-08-22

Each component is not tested for conformity with all appropriate written specifications for purity, strength, and quality.

Lupin Limited · Pithampur · Drugs · 2025-07-17

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →